International Workshop on
Acute Leukemias (iwAL) 2021

21 – 22 January 2021

 

The Post-ASH 2020 Virtual iwAL workshop will be held on the 21st and 22nd January 2021 online. The program will cover ALL on Day 1 and AML on Day 2 and will have a series of short presentations from invited experts on selected abstracts from the 62nd ASH Annual Meeting with interactive panel discussions after each session.

Apply for registration for iwAL here

This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.

Agenda (all times EST)

 

Thursday 21st January 2021 – ALL

09.55am EST Welcome Day 1: Dieter Hoelzer/Dan DeAngelo

10.00-10.50 Session 1: MRD/Translational Research | Chairs: Sabina Chiaretti & Dieter Hoelzer

• Monitoring MRD Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study: L. Muffly – 975

• Ultrasensitive Next-Generation Sequencing-Based MRD Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes: N. Short – 583

• Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib: Yuya Sasaki – 398

• Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials: J. Ribera – 1902

Discussion – panellists: D. Hoelzer, S. Chiaretti, L, Muffly, N.Short, Y. Sasaki, J, Ribera

10.50 – 11.45 Session 2: CAR T-Cell | Chairs: Noelle Frey & Bijal Shah

• Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL): Peihua Lu – 159

• ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies: C.Roddie – 160

• The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: He Huang – 499

• Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement: E. Jacoby – 2798

Discussion – panellists: N.Frey, B. Shah, P.Lua, C.Roddie, H.Huang, E.Jacoby

11.45 – 12.30 Session 3: Immunotherapy | Chairs: Dan DeAngelo & Nicola Goekbucket

• First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial): N.Goekbuget – 267

• Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA): N. Goekbuget – 2795

• Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial: F. Locatelli – 268

Discussion – panellists: D.DeAngelo, N. Goekbuget, F. Locatelli, D.Hoelzer

Day 1 wrap up


Day 2 Friday 22nd, 2020 – AML

09.55 – 10.00am EST Welcome Day 2: Naval Daver/Richard Stone

10.00-10.50 Session 1: Immunotherapy | Chairs: Marion Subklewe & Bob Lowenburg

• The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results: D. Sallman – 330

• Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia: I. Aldoss – 331

• Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study: F. Ravandi – 460

• Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings: J. Garcia – 170

Discussion – panellists: M.Subklewe, B.Lowenburg, D. Sallman, I. Aldoss, F. Ravandi, J. Garcia

10.50 -11.40 Session 2: FLT3 in AML | Chairs: Naval Daver & Mark Levis

• A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results: K. Pratz – 24

• Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study: N. Daver – 333

• Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib: A. Perl – 334

• Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I Versus Type II FLT3-Inhibitors (FLT3i’s): M. Yilmaz 335

Discussion – panellists: N.Daver, M. Levis, K. Pratz, M. Yilmaz

11.40 -12.30 Session 3: Controversies in AML | Chairs: Marina Konopleva & Andrew Wei

Who should receive maintenance therapy and when?

• CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial; G. Roboz – 692

• CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial: A.Wei 1036

Should patients with pre-transplant MRD receive further pre-transplant therapy or not?

• Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia; M. Stahl – 273

Is there a role for interim BM analysis and re-induction?

• Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial: C. Rollig – 458

Discussion – panellists: M.Konopleva, A.Wei, G.Roboz, M.Stahl, C.Rollig, C.Craddock

12.30-13.30 Session 4 : Novel therapies/updates in AML & BPBCN | Chairs: Courtney DiNardo & Gail Roboz

• Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia: E. Wang 115

• Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders: J. Lancet 635

• Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML: C. Lachoweiz – 332

• Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: E. Stein 114

• Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): N. Pemmaraju 167

Discussion – panellists: C. DiNardo, G.Roboz, E.Wang, J.Lancet, C.Lachoweiz, E.Stein, N, Pemmaraju

Day 2 wrap up

End of Virtual Workshop

Apply for registration for iwAL here

This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter